|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT) - NACGED0507ACN0123LT
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-2) - NACGED0507ACN0123B
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-1) - NACGED0507ACN0123A
100 Clinical Results associated with SM2 Software & Services Management SA
0 Patents (Medical) associated with SM2 Software & Services Management SA
100 Deals associated with SM2 Software & Services Management SA
100 Translational Medicine associated with SM2 Software & Services Management SA